{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:12Z","timestamp":1793939412710,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.msard.2024.106222","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T17:19:40Z","timestamp":1733764780000},"page":"106222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["MOG-IgG is rare in AQP4-IgG seronegative NMO phenotype in Brazil"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-0842","authenticated-orcid":false,"given":"Denison Alves","family":"Pedrosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo B.P.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia","family":"Talim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane A.R.","family":"Welter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre G.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo P.","family":"Christo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales","family":"Pons\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.H.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazielle","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo F.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-681X","authenticated-orcid":false,"given":"Marco A.","family":"Lana-Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"November","key":"10.1016\/j.msard.2024.106222_bib0001","article-title":"Five-year visual outcomes after optic neuritis in anti-mog antibody-associated disease","volume":"56","author":"Akaishi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.106222_bib0002","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international mogad panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.106222_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000702","article-title":"Hla association in Mog-Igg- and Aqp4-Igg-related disorders of the Cns in the Dutch population","volume":"7","author":"Bruijstens","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.106222_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"issue":"21","key":"10.1016\/j.msard.2024.106222_bib0005","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of Cns Mog autoimmunity in adults: the mogador study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2024.106222_bib0006","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"n.d.. KidBioSEP, and OFSEP study group Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.106222_bib0007","series-title":"My\u00e9lite Subaigu\u00eb Compliqu\u00e9e De N\u00e9vrite Optique","author":"Devic","year":"1894"},{"issue":"3","key":"10.1016\/j.msard.2024.106222_bib0008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2024.106222_bib0009","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1177\/13524585221093789","article-title":"Serum Mog-Igg in children meeting multiple sclerosis diagnostic criteria","volume":"28","author":"Fadda","year":"2022","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.106222_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200183","article-title":"Timing of Mog-Igg testing is key to 2023 Mogad diagnostic criteria","volume":"11","author":"Forcadela","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2024.106222_bib0011","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/13524585231172960","article-title":"Serum Mog-Igg titers should be performed routinely in the diagnosis and follow-up of Mogad: commentary","volume":"29","author":"Gastaldi","year":"2023","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2024.106222_bib0012","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/acn3.51378","article-title":"No strong Hla association with Mog antibody disease in the Uk population","volume":"8","author":"Grant-Peters","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2024.106222_bib0013","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of Aqp4-Igg-negative nmo spectrum disorder patients are Mog-Igg positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.106222_bib0014","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.106222_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor","year":"2023","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2024.106222_bib0016","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/jnnp-2014-309761","article-title":"Bright spotty lesions on the spinal cord: an Additional Mri indicator of neuromyelitis optica spectrum disorder?","volume":"86","author":"Hyun","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"7","key":"10.1016\/j.msard.2024.106222_bib0017","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to Mog and Aqp4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106222_bib0018","series-title":"Censo Demogr\u00e1fico 2022 : Identifica\u00e7\u00e3o \u00c9tnico-Racial Da Popula\u00e7\u00e3o","year":"2023"},{"issue":"3","key":"10.1016\/j.msard.2024.106222_bib0019","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated cns conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"issue":"12","key":"10.1016\/j.msard.2024.106222_bib0020","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in Mog-antibody disease: a Uk study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"issue":"3","key":"10.1016\/j.msard.2024.106222_bib0021","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.msard.2015.04.001","article-title":"On the origin of neurostatus","volume":"4","author":"Kappos","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.106222_bib0022","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with Aquaporin-4 and Myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2024.106222_bib0023","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.106222_bib0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammat."},{"issue":"11","key":"10.1016\/j.msard.2024.106222_bib0026","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1055\/s-0043-1777002","article-title":"Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience","volume":"81","author":"Messias","year":"2023","journal-title":"Arq. Neuropsiquiatr."},{"issue":"2","key":"10.1016\/j.msard.2024.106222_bib0027","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/13524585211018987","article-title":"Contrasting the brain imaging features of Mog-antibody disease, with Aqp4-antibody Nmosd and multiple sclerosis","volume":"28","author":"Messina","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106222_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103884","article-title":"Prevalence, incidence, and season distribution of Mog antibody-associated disease in the province of Verona, Italy","volume":"63","author":"Orlandi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2024.106222_bib0029","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1177\/1352458514521503","article-title":"Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India","volume":"20","author":"Pandit","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106222_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2018.07.026","article-title":"Lower Frequency of Antibodies to Mog in Brazilian Patients with Demyelinating Diseases: An Ethnicity Influence?","volume":"25","author":"Papais-Alvarenga","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.msard.2024.106222_bib0031","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology."},{"issue":"Pt 3","key":"10.1016\/j.msard.2024.106222_bib0032","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/brain\/107.3.951","article-title":"Bilateral optic neuritis. A long-term follow-up","volume":"107","author":"Parkin","year":"1984","journal-title":"Brain."},{"issue":"4","key":"10.1016\/j.msard.2024.106222_bib0033","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, Aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2024.106222_bib0034","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2024.106222_bib0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.106222_bib0036","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between Mog antibody-positive and Aqp4 antibody-positive Nmo spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.106222_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (Mogad): a review of clinical and Mri features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.106222_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104488","article-title":"Estimated prevalence of aqp4 positive neuromyelitis optica spectrum disorder and Mog antibody associated disease in S\u00e3o Paulo, Brazil","volume":"70","author":"Silva","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.106222_bib0039","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.106222_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.msard.2024.106222_bib0042","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2024.106222_bib0043","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology."},{"issue":"12","key":"10.1016\/j.msard.2024.106222_bib0044","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s11427-015-4997-y","article-title":"\"Autoantibody to Mog suggests two distinct clinical subtypes of Nmosd\"","volume":"59","author":"Yan","year":"2016","journal-title":"Sci. China. Life. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T20:59:40Z","timestamp":1738184380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824007983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"alternative-id":["S2211034824007983"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106222","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MOG-IgG is rare in AQP4-IgG seronegative NMO phenotype in Brazil","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106222"}}